Global Low Molecular Weight Heparin Market Growth 2019-2024

Low Molecular Weight Heparin (LMWHs) is derived from UFH (Unfractionated heparin) by such processes as chemical degradation, enzymatic depolymerisation and gamma-radiation cleavage.
Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of varying molecular weights, from 5000 to over 40,000 Daltons, make up polydisperse pharmaceutical-grade heparin. LMWHs, in contrast, consist of only short chains of polysaccharide. LMWHs are defined as heparin salts having an average molecular weight of less than 8000 Da and for which at least 60% of all chains have a molecular weight less than 8000 Da.
In 2016, in term of volume, the global Low molecular weight heparin market is led by china, capturing about 49.57% of global low molecular weight heparin production. In term of revenue, USA is the second’s largest market with the share of 30.49%.
At present, the major manufacturers of Low Molecular Weight Heparin are Aspen, Sanofi-aventis, Pfizer, Opocrin, CSBIO, Dongying Tiandong Pharmaceutical, Changzhou Qianhong Bio-pharma, Techdow, Yantai Dongcheng Pharmaceutical Group, etc. Aspen, Sanofi-aventis and Pfizer are industry-leading manufacturers of top-quality Low Molecular Weight Heparins.
China is a big low molecular weight heparin production country, especially Heparin API, but it is not strong country. According to our research and analysis, manufacturers from United States and Europe are the major leaders in the international market of low molecular weight heparin. Manufacturers from China are immature in technology. There is large space in the China market, as well as big gap between international brands and local brands on price.
In application, low molecular weight heparin downstream is wide and recently low molecular weight heparin has acquired increasing significance in various fields of treatment of venous thromboembolism, complications of pregnancy, cardioversion of atrial fibrillation/flutter and others.
Globally, the low molecular weight heparin market is mainly driven by growing demand for treatment of venous thromboembolism which accounts for nearly 65.24% of total downstream consumption of low molecular weight heparin in global.

According to this study, over the next five years the Low Molecular Weight Heparin market will register a 5.6% CAGR in terms of revenue, the global market size will reach US$ 380 million by 2024, from US$ 270 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Low Molecular Weight Heparin business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Low Molecular Weight Heparin market by product type, application, key manufacturers and key regions and countries.

This study considers the Low Molecular Weight Heparin value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Enoxaparin
Dalteparin
Tinzaparin
Fraxiparine
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Treatment of Venous Thromboembolism
Complications of Pregnancy
Cardioversion of Atrial Fibrillation/Flutter
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Aspen
Sanofi-aventis
Pfizer
Opocrin
CSBIO
Dongying Tiandong Pharmaceutical
Changzhou Qianhong Bio-pharma
Techdow
Yantai Dongcheng Pharmaceutical Group

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Low Molecular Weight Heparin consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Low Molecular Weight Heparin market by identifying its various subsegments.
Focuses on the key global Low Molecular Weight Heparin manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Low Molecular Weight Heparin with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Low Molecular Weight Heparin submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.